Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine

Viral Immunology

Volumn 23, Issue 5, 2010, Pages 509-519

  Roberts, Anjeanette ^a,c   Lamirande, Elaine W ^a   Vogel, Leatrice ^a   Baras, Benoît ^b   Goossens, Geneviève ^b   Knott, Isabelle ^b   Chen, Jun ^a   Ward, Jerrold M ^a,c,d   Vassilev, Ventzislav ^b   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; NEUTRALIZING ANTIBODY; PROPIOLACTONE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HAMSTER; IMMUNOGENICITY; LIVER; LUNG; MOUSE; NONHUMAN; SARS CORONAVIRUS; VACCINATION; VIRUS INACTIVATION; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CRICETINAE; DISINFECTANTS; FEMALE; IMMUNIZATION, SECONDARY; LIVER; LUNG; MESOCRICETUS; MICE; MICE, INBRED BALB C; PROPIOLACTONE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL ANALYSIS; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES; VIRUS INACTIVATION;

CRICETINAE; MESOCRICETUS AURATUS; MUS; SARS CORONAVIRUS;

EID: 77957732313     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0028     Document Type: Article

References (35)

1. Wang JT, and Chang SC: Severe acute respiratory syndrome. Curr Opin Infect Dis 2004;17:143-148.
2. Guan Y, Zheng BJ, He YQ, et al.: Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science 2003;302:276-278.
3. Lau SK, Woo PC, Li KS, et al.: Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102:14040-14045.
4. Li W, Shi Z, Yu M, et al.: Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-679.
5. Li F, Li W, Farzan M, and Harrison SC: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309:1864-1868.
6. Roberts A, Lamirande EW, Vogel L, et al.: Animal models and vaccines for SARS-CoV infection. Virus Res 2008;133:20-32.
7. Enjuanes L, Dediego ML, Alvarez E, et al.: Vaccines to prevent severe acute respiratory syndrome coronavirusinduced disease. Virus Res 2008;133:45-62.
8. Roper RL, and Rehm KE: SARS vaccines: where are we? Expert Rev Vaccines 2009;8:887-898.
9. Lin JT, Zhang JS, Su N, et al.: Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther 2007;12:1107-1113.
10. Martin JE, Louder MK, Holman LA, et al.: A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008;26:6338-6343.
11. Roberts A, Wood J, Subbarao K, et al.: Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, U. K. Vaccine 2006;24:7056-7065.
12. Bisht H, Roberts A, Vogel L, et al.: Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005;334:160-165.
13. See RH, Zakhartchouk AN, Petric M, et al.: Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 2006;87:641-650.
14. Subbarao K, McAuliffe J, Vogel L, et al.: Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004;78:3572-3577.
15. Roberts A, Vogel L, Guarner J, et al.: Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 2005;79:503-511.
16. Lamirande EW, DeDiego ML, Roberts A, et al.: A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol 2008;82:7721-7724.
17. Poon L L M, Chan KH, Wong OK, et al.: Early diagnosis of SARS Coronavirus infection by real time RT-PCR. J Clin Virol 2003;28:233-238.
18. Roberts A, Thomas WD, Guarner J, et al.: Therapy with a severe acute respiratory syndrome-associated coronavirusneutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 2006;193:685-692.
19. Suni MA, Picker LJ, and Maino VC: Detection of antigenspecific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998;212:89-98.
20. Maecker HT: Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 2009;485:375-391.
21. Kapadia SU, Rose JK, Lamirande E, et al.: Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005;340:174-182.
22. Geeraedts F, Bungener L, Pool J, et al.: Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir Viruses 2008;2:41-51.
23. Ping LH, and Lemon SM: Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol 1992;66:2208-2216.
24. Moghaddam A, Olszewska W, Wang B, et al.: A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006;12:905-907.
25. Tsunetsugu-Yokota Y, Ato M, Takahashi Y, et al.: Formalintreated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses. Jpn J Infect Dis 2007;60:106-112.
26. Giannini SL, Hanon E, Moris P, et al.: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-5949.
27. Mettens P, Dubois PM, Demoitie MA, et al.: Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS, S vaccine antigen. Vaccine 2008;26:1072-1082.
28. Baras B, Bouveret N, Devaster J-M, et al.: A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir Viruses 2008;2:251-260.
29. Garcon N, Chomez P, and Van Mechelen M: GlaxoSmith-Kline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-739.
30. Garcon N, Heppner DG, and Cohen J: Development of RTS, S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003;2:231-238.
31. Vandepapeliere P, Rehermann B, Koutsoukos M, et al.: Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 2005;23:2591-2601.
32. Vandepapeliere P, Horsmans Y, Moris P, et al.: Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008;26:1375-1386.
33. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al.: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007;370:580-589.
34. See RH, Petric MK, Lawrence DJ, et al.: Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J Gen Virol 2008;89:2136-2146.
35. Czub M, Weingartl H, Czub S, et al.: Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005;23:2273-2279.